SlideShare a Scribd company logo
1 of 8
Download to read offline
Biopharma PEG https://www.biochempeg.com
Antibody–Oligonucleotide Conjugates (AOCs) in
Clinical Trials
The development of oligonucleotide-based gene therapies has been in full swing over the
past few years due to their unique advantage of regulating gene expression.
Oligonucleotides are short DNA or RNA oligomers between 20 and 60 units in length,
which can be synthesized or found naturally as single-stranded (ss) or double-stranded
(ds) oligomers. The introduction of oligonucleotide drugs has broadened the means and
boundaries of disease treatment and brought new hope for the treatment of many
diseases.
However, unmodified oligonucleotides are difficult to cross through the cellular membrane
and blood-brain barrier due to their high molecular weight, high hydrophilicity and
negative charge, as well as their low in vivo stability and rapid host clearance outside cells.
Currently, the main approved oligonucleotide drug delivery systems are the LNP delivery
system and the GalNAc delivery system, but neither is capable of drug-targeted
delivery outside the liver. An emerging strategy to deliver oligonucleotides to tissues
outside of the liver is by linking them to monoclonal antibodies (mAbs), to form antibody–
oligonucleotide conjugates (AOCs).
AOC Drugs Market Landscape
Currently, a number of companies are working in the AOC space, mainly
including Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, and Denali
Therapeutics.
Avidity Biosciences (AOC 1001, AOC 1020)
Avidity Biosciences, founded in 2013, is a biopharmaceutical company that is pioneering
AOC therapies for the treatment of inherited muscle diseases. At its inception , Avidity
envisioned tissue-specific delivery of small interfering RNA (siRNA)-nanoparticles via
antibodies, but that didn't go well, as antibodies are difficult to achieve effective delivery of
Biopharma PEG https://www.biochempeg.com
siRNA-nanoparticles. To ensure effective loading, the researchers tried to conjugate
antibodies directly to siRNA, which led to the design of the AOC drug.
Avidity's AOC programs mainly offer treatment options for patients with myotonic
dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne
Muscular Dystrophy (DMD), etc.
Figure. Avidity Biosciences Pipeline, source: Avidity Biosciences official website
AOC1001
AOC 1001, Avidity's lead product candidate developed for the treatment of dystrophic
myotonic dystrophy type 1 (DM1), consists of a proprietary monoclonal antibody that
binds to the transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DMPK mRNA,
which is designed to address the root cause of DM1 by reducing levels of DMPK
RNA. Avidity is currently conducting the Phase I/II MARINA and MARINA-OLE
studies of AOC 1001 for the treatment of DM1, and AOC 1001 is the first AOC drug to
enter the clinic.
Biopharma PEG https://www.biochempeg.com
Figure. AOC-1001 for DM1, source: Avidity Biosciences official website
In preclinical studies, AOC 1001 successfully delivered siRNA to muscle cells, resulting in
a long-lasting, dose-dependent reduction of DMPK RNA in a variety of muscles, including
skeletal, cardiac, and smooth muscle.
Avidity announced positive topline data for AOC 1001 from the Phase 1/2 MARINA trial at
the 75th Annual Meeting of the American Academy of Neurology (AAN) in April 2023,
which demonstrated functional improvement in multiple clinical outcome metrics, disease
modification, and favorable safety and tolerability profiles for adult DM1 patients.
FDA and EMA have granted Orphan Designation for AOC 1001 and the FDA has granted
AOC 1001 Fast Track Designation.
AOC1020
AOC1020, an AOC drug consisting of a TfR1 antibody coupled to a siRNA targeting DUX4
mRNA, was developed for the treatment of facioscapulohumeral muscular dystrophy
(FSHD). FSHD is one of the most common clinically inherited muscle disorders caused by
aberrant expression of the DUX4 gene in skeletal muscle, leading to skeletal muscle
atrophy and impaired muscle function through a series of downstream events. There are
currently no approved therapeutic options for this disease, and medical care is
primarily focused on physical therapy, exercise, pain management, and orthopedic
Biopharma PEG https://www.biochempeg.com
interventions, with other therapies in development that do not directly target DUX4 as a
disease driver.
Figure. AOC1020 for FSHD, source: Avidity Biosciences official website
Preclinical data show that AOC 1020 inhibits DUX4 mRNA expression, decreasing DUX4
protein levels and reducing downstream gene expression. AOC 1020 is currently in
Phase 1/2 development as part of the FORTITUDE™ trial in adults with FSHD. The
FDA and the EMA have granted Orphan designation for AOC 1020 and the FDA has
granted AOC 1020 Fast Track designation.
Dyne Therapeutics(DYNE-101, DYNE-251)
Dyne Therapeutics is a biopharmaceutical company developing targeted therapies for
serious muscle diseases. The company focuses on three major rare muscle diseases,
including DM1, DMD and FSHD. Dyne is developing novel oligonucleotide therapies with
its proprietary FORCE™ platform, which targets the TFR-1 receptor, a highly expressed
receptor on the surface of muscle cells, and engineers therapeutic molecules by ligating
antibodies to oligonucleotides for the treatment of severe muscle diseases.
Biopharma PEG https://www.biochempeg.com
Figure. Dyne Therapeutics pipeline, source: Dyne Therapeutics official website
DYNE-101
DYNE-101 is an investigational AOC being evaluated in the Phase I/II global
ACHIEVE trial, for treatment of DM1. It consists of an antigen-binding fragment antibody
(Fab) conjugated to an antisense oligonucleotide (ASO) designed to enable targeted
muscle tissue delivery that reduces toxic DMPK RNA in the nucleus, releases splicing
proteins, allows normal mRNA processing and translation of normal proteins, and
potentially stops or reverses disease.
In May 2023, the EMA has granted orphan drug designation for DYNE-101.
DYNE-251
DYNE-251 is an AOC developed for patients with DMD amenable to skipping exon 51,
consisting of a phosphorodiamidate morpholino oligomer (PMO) conjugated to a Fab
fragment. DYNE-251 can target binding to TfR1, which is highly expressed in the target
muscle tissues. It is designed to enable targeted muscle tissue delivery and promote
exon skipping in the nucleus, allowing muscle cells to create a truncated, functional
dystrophin protein, with the goal of stopping or reversing disease progression. DYNE-251
is currently in Phase I/II DELIVER global clinical trials. Previously, the U.S. Food and
Drug Administration (FDA) granted Fast Track designation for DYNE-251.
Tallac Therapeutics (TAC-001)
Biopharma PEG https://www.biochempeg.com
Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power
of innate and adaptive immunity to fight cancer. Tallac's immunotherapy candidate
pipeline stems from the company's novel Toll-like receptor agonist antibody conjugate
(TRAAC) platform, to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for
targeted immune activation via systemic administration.
Figure. Tallac Therapeutics pipelines, source: Tallac Therapeutics official website
TAC-001
TAC-001, an important drug candidate for Tallac, is an AOC consisting of a potent toll-like
receptor 9 agonist (T-CpG) conjugated to an antibody against CD22, which delivers
T-CpG to B cells by binding to CD22, which in turn leads to internalization of TAC-001 as
well as TLR9 signaling, B cell activation, and a series of immune responses. The innate
and adaptive immune responses triggered by TAC-001 show potent, curative, and durable
single-agent antitumor activity in checkpoint inhibitor-resistant and refractory tumor
models. TAC-001 is currently in Phase I/II clinical stage for the potential treatment of
solid tumors.
Denali Therapeutics (DNL310)
Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative
diseases, has developed a proprietary transport vehicle (TV) technology platform that
enables therapeutic biomolecules, including enzymes, antibodies, proteins, and
oligonucleotides, to cross the blood-brain barrier more efficiently. In addition, Denali
Biopharma PEG https://www.biochempeg.com
regards TfR1 as a gateway to the brain. Cells lining the blood-brain barrier express TfR1,
making TfR1 an ideal pathway for oligonucleotides, proteins and antibody drugs to enter
the central nervous system.
DNL310
DNL310 is a fusion protein drug consisting of an IDS protein bound to Denali's Enzymatic
Transport Vehicle (ETV). Denali's ETV platform contains engineered Fc fragments that
bind to natural transport receptors, such as transferrin receptor, which are expressed at
the BBB and deliver TV and its therapeutic cargo to the brain through receptor-mediated
transcytosis. DNL310 delivers IDS to lysosomes, where it is needed to break down GAGs.
DNL310 is engineered for broad delivery of IDS into cells and tissues throughout the body,
including the brain.
Figure. DNL310 mechanism of action, source: Denali Therapeutics official website
In March 2021, the U.S. FDA granted Fast Track designation to DNL310 for the treatment
of MPS II. In May 2022, the EMA granted DNL310 Priority Medicines designation.
In June 2023, Denali announced Phase I/II clinical results for DNL310 for the treatment of
MPS II. The data showed a significant reduction in serum Neurofilament Light (NfL) levels
of up to 64% in MPS II patients compared to baseline. A clinical Phase II/III trial of
DNL310 is currently underway worldwide.
Conclusion
Biopharma PEG https://www.biochempeg.com
Currently, there are only a few AOC drugs under development, and the progress is a little
behind compared with other drug conjugates, the effectiveness, and safety still need to be
further certified, leaving a long way to go before they can be routinely used in the clinic.
However, nucleic acid drugs are regarded as the third wave of biopharmaceuticals and
large molecule biopharmaceuticals, and oligonucleotide therapy itself has been approved
in the past few years for the treatment of rare diseases, which fully proves the efficacy and
safety of this therapy. In this case, it can be expected that AOC, as a new type of drug
conjugate, will make a breakthrough in the field of rare disease therapy.
References:
1. Antibody–oligonucleotide conjugates enter the clinic. Nature Reviews Drug Discovery.
2. https://www.sec.gov/Archives/edgar/data/1599901/000119312521232444/d203435dex
991.htm
3. https://www.aviditybiosciences.com/wp-content/uploads/2023/04/P.3.007-FORTITUDE
-TIP_AAN-2023_ELECTRONIC-Poster_v5.0_Final.pdf
4. https://www.dyne-tx.com/
5. https://www.biospace.com/article/releases/dyne-therapeutics-receives-european-medi
cines-agency-ema-orphan-drug-designation-for-dyne-101/?s=63.
6. https://www.tallactherapeutics.com/news/tallac-therapeutics-announces-first-patient-do
sed-with-tac-001-a-first-in-class-toll-like-receptor-9-agonist-antibody-conjugate-in-a-phas
e-1-2-study-for-patients-with-advanced-solid-tumors/
7. Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with
DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome). Retrieved June 20, 2023
from https://www.denalitherapeutics.com/investors/press-release?id=9391&type=api.
Related Articles:
9 Types of Drug Conjugates Overview
Small Molecule-Drug Conjugates (SMDCs): Novel Targeted Therapy
Aptamer-Drug Conjugate (ApDC): Current Research Progress
Peptide-Drug Conjugates (PDCs): Development Status & Research Progress

More Related Content

Similar to Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf

Nucleic acid therapeutics recent development
Nucleic acid therapeutics recent developmentNucleic acid therapeutics recent development
Nucleic acid therapeutics recent developmentDoriaFang
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfDoriaFang
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfDoriaFang
 
Prota cs and targeted protein degradation
Prota cs and targeted protein degradationProta cs and targeted protein degradation
Prota cs and targeted protein degradationDoriaFang
 
PROTAC Technology: An Effective Targeted Protein Degrader.pdf
PROTAC Technology: An Effective Targeted Protein Degrader.pdfPROTAC Technology: An Effective Targeted Protein Degrader.pdf
PROTAC Technology: An Effective Targeted Protein Degrader.pdfDoriaFang
 
Peptide drug conjugates (pd cs) new generation of targeted cancer treatment
Peptide drug conjugates (pd cs) new generation of targeted cancer treatmentPeptide drug conjugates (pd cs) new generation of targeted cancer treatment
Peptide drug conjugates (pd cs) new generation of targeted cancer treatmentDoriaFang
 
i1552-5783-57-2-372
i1552-5783-57-2-372i1552-5783-57-2-372
i1552-5783-57-2-372Ryo Iwata
 
Engineered scaffold protein
Engineered scaffold proteinEngineered scaffold protein
Engineered scaffold proteinDRMOHITKHER
 
Duchenne drug tested for muscular dystrophy as drug repurposing
Duchenne drug tested for muscular dystrophy as drug repurposingDuchenne drug tested for muscular dystrophy as drug repurposing
Duchenne drug tested for muscular dystrophy as drug repurposingmovvaharshavardhan
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfDoriaFang
 
Drug Transport and drug target.pptx
Drug Transport and drug target.pptxDrug Transport and drug target.pptx
Drug Transport and drug target.pptxmrcopyxerox
 
GENE Expression TARGETED THERAPY.pdf
GENE Expression  TARGETED THERAPY.pdfGENE Expression  TARGETED THERAPY.pdf
GENE Expression TARGETED THERAPY.pdfmohieeldien elsayed
 
PROTAC Technology A New Application In Influenza Vaccines.pdf
PROTAC Technology A New Application In Influenza Vaccines.pdfPROTAC Technology A New Application In Influenza Vaccines.pdf
PROTAC Technology A New Application In Influenza Vaccines.pdfDoriaFang
 
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...DoriaFang
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfDoriaFang
 
Therapeutic antibodies for autoimmunity and inflammation
Therapeutic antibodies for autoimmunity and inflammationTherapeutic antibodies for autoimmunity and inflammation
Therapeutic antibodies for autoimmunity and inflammationNational Institute of Biologics
 

Similar to Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf (20)

Nucleic acid therapeutics recent development
Nucleic acid therapeutics recent developmentNucleic acid therapeutics recent development
Nucleic acid therapeutics recent development
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
 
Prota cs and targeted protein degradation
Prota cs and targeted protein degradationProta cs and targeted protein degradation
Prota cs and targeted protein degradation
 
PROTAC Technology: An Effective Targeted Protein Degrader.pdf
PROTAC Technology: An Effective Targeted Protein Degrader.pdfPROTAC Technology: An Effective Targeted Protein Degrader.pdf
PROTAC Technology: An Effective Targeted Protein Degrader.pdf
 
Peptide drug conjugates (pd cs) new generation of targeted cancer treatment
Peptide drug conjugates (pd cs) new generation of targeted cancer treatmentPeptide drug conjugates (pd cs) new generation of targeted cancer treatment
Peptide drug conjugates (pd cs) new generation of targeted cancer treatment
 
i1552-5783-57-2-372
i1552-5783-57-2-372i1552-5783-57-2-372
i1552-5783-57-2-372
 
Engineered scaffold protein
Engineered scaffold proteinEngineered scaffold protein
Engineered scaffold protein
 
Duchenne drug tested for muscular dystrophy as drug repurposing
Duchenne drug tested for muscular dystrophy as drug repurposingDuchenne drug tested for muscular dystrophy as drug repurposing
Duchenne drug tested for muscular dystrophy as drug repurposing
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
 
Drug Transport and drug target.pptx
Drug Transport and drug target.pptxDrug Transport and drug target.pptx
Drug Transport and drug target.pptx
 
GENE Expression TARGETED THERAPY.pdf
GENE Expression  TARGETED THERAPY.pdfGENE Expression  TARGETED THERAPY.pdf
GENE Expression TARGETED THERAPY.pdf
 
Cancer nanotechnology
Cancer nanotechnologyCancer nanotechnology
Cancer nanotechnology
 
PROTAC Technology A New Application In Influenza Vaccines.pdf
PROTAC Technology A New Application In Influenza Vaccines.pdfPROTAC Technology A New Application In Influenza Vaccines.pdf
PROTAC Technology A New Application In Influenza Vaccines.pdf
 
2012-Feyen-EDIM-FutureOncology.pdf
2012-Feyen-EDIM-FutureOncology.pdf2012-Feyen-EDIM-FutureOncology.pdf
2012-Feyen-EDIM-FutureOncology.pdf
 
TREATMENT LHON.docx
TREATMENT LHON.docxTREATMENT LHON.docx
TREATMENT LHON.docx
 
Homspera march2010
Homspera march2010Homspera march2010
Homspera march2010
 
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
 
Therapeutic antibodies for autoimmunity and inflammation
Therapeutic antibodies for autoimmunity and inflammationTherapeutic antibodies for autoimmunity and inflammation
Therapeutic antibodies for autoimmunity and inflammation
 

More from DoriaFang

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfDoriaFang
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfDoriaFang
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfDoriaFang
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfDoriaFang
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfDoriaFang
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfDoriaFang
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDoriaFang
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfDoriaFang
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfDoriaFang
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfDoriaFang
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfDoriaFang
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfDoriaFang
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfDoriaFang
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfDoriaFang
 
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdfNectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdfDoriaFang
 
PROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdfPROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdfDoriaFang
 
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdfAptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdfDoriaFang
 
Summary of Molecular Glues Approved or in Clinical Trial.pdf
Summary of Molecular Glues Approved or in Clinical Trial.pdfSummary of Molecular Glues Approved or in Clinical Trial.pdf
Summary of Molecular Glues Approved or in Clinical Trial.pdfDoriaFang
 
FRα Targeting ADCs for Ovarian cancer.pdf
FRα Targeting ADCs for Ovarian cancer.pdfFRα Targeting ADCs for Ovarian cancer.pdf
FRα Targeting ADCs for Ovarian cancer.pdfDoriaFang
 
FRα Another Hot Target In The ADC Field.pdf
FRα Another Hot Target In The ADC Field.pdfFRα Another Hot Target In The ADC Field.pdf
FRα Another Hot Target In The ADC Field.pdfDoriaFang
 

More from DoriaFang (20)

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdf
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
 
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdfNectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
 
PROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdfPROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdf
 
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdfAptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
 
Summary of Molecular Glues Approved or in Clinical Trial.pdf
Summary of Molecular Glues Approved or in Clinical Trial.pdfSummary of Molecular Glues Approved or in Clinical Trial.pdf
Summary of Molecular Glues Approved or in Clinical Trial.pdf
 
FRα Targeting ADCs for Ovarian cancer.pdf
FRα Targeting ADCs for Ovarian cancer.pdfFRα Targeting ADCs for Ovarian cancer.pdf
FRα Targeting ADCs for Ovarian cancer.pdf
 
FRα Another Hot Target In The ADC Field.pdf
FRα Another Hot Target In The ADC Field.pdfFRα Another Hot Target In The ADC Field.pdf
FRα Another Hot Target In The ADC Field.pdf
 

Recently uploaded

Pitch Deck Teardown: Goodcarbon's $5.5m Seed deck
Pitch Deck Teardown: Goodcarbon's $5.5m Seed deckPitch Deck Teardown: Goodcarbon's $5.5m Seed deck
Pitch Deck Teardown: Goodcarbon's $5.5m Seed deckHajeJanKamps
 
The Art of Decision-Making: Navigating Complexity and Uncertainty
The Art of Decision-Making: Navigating Complexity and UncertaintyThe Art of Decision-Making: Navigating Complexity and Uncertainty
The Art of Decision-Making: Navigating Complexity and Uncertaintycapivisgroup
 
Presentation4 (2) survey responses clearly labelled
Presentation4 (2) survey responses clearly labelledPresentation4 (2) survey responses clearly labelled
Presentation4 (2) survey responses clearly labelledCaitlinCummins3
 
Beyond Numbers A Holistic Approach to Forensic Accounting
Beyond Numbers A Holistic Approach to Forensic AccountingBeyond Numbers A Holistic Approach to Forensic Accounting
Beyond Numbers A Holistic Approach to Forensic AccountingYourLegal Accounting
 
Unlocking Growth The Power of Outsourcing for CPA Firms
Unlocking Growth The Power of Outsourcing for CPA FirmsUnlocking Growth The Power of Outsourcing for CPA Firms
Unlocking Growth The Power of Outsourcing for CPA FirmsYourLegal Accounting
 
Challenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
Challenges and Opportunities: A Qualitative Study on Tax Compliance in PakistanChallenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
Challenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistanvineshkumarsajnani12
 
如何办理(SUT毕业证书)斯威本科技大学毕业证成绩单本科硕士学位证留信学历认证
如何办理(SUT毕业证书)斯威本科技大学毕业证成绩单本科硕士学位证留信学历认证如何办理(SUT毕业证书)斯威本科技大学毕业证成绩单本科硕士学位证留信学历认证
如何办理(SUT毕业证书)斯威本科技大学毕业证成绩单本科硕士学位证留信学历认证ogawka
 
Powerpoint showing results from tik tok metrics
Powerpoint showing results from tik tok metricsPowerpoint showing results from tik tok metrics
Powerpoint showing results from tik tok metricsCaitlinCummins3
 
obat aborsi bandung wa 081336238223 jual obat aborsi cytotec asli di bandung9...
obat aborsi bandung wa 081336238223 jual obat aborsi cytotec asli di bandung9...obat aborsi bandung wa 081336238223 jual obat aborsi cytotec asli di bandung9...
obat aborsi bandung wa 081336238223 jual obat aborsi cytotec asli di bandung9...yulianti213969
 
The Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdf
The Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdfThe Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdf
The Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdfbelieveminhh
 
Elevate Your Online Presence with SEO Services
Elevate Your Online Presence with SEO ServicesElevate Your Online Presence with SEO Services
Elevate Your Online Presence with SEO ServicesHaseebBashir5
 
A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...
A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...
A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...prakheeshc
 
Navigating Tax Season with Confidence Streamlines CPA Firms
Navigating Tax Season with Confidence Streamlines CPA FirmsNavigating Tax Season with Confidence Streamlines CPA Firms
Navigating Tax Season with Confidence Streamlines CPA FirmsYourLegal Accounting
 
Most Visionary Leaders in Cloud Revolution, Shaping Tech’s Next Era - 2024 (2...
Most Visionary Leaders in Cloud Revolution, Shaping Tech’s Next Era - 2024 (2...Most Visionary Leaders in Cloud Revolution, Shaping Tech’s Next Era - 2024 (2...
Most Visionary Leaders in Cloud Revolution, Shaping Tech’s Next Era - 2024 (2...CIO Look Magazine
 
A DAY IN LIFE OF A NEGOTIATOR By Pondicherry University MBA Students.pptx
A DAY IN LIFE OF A NEGOTIATOR By Pondicherry University MBA Students.pptxA DAY IN LIFE OF A NEGOTIATOR By Pondicherry University MBA Students.pptx
A DAY IN LIFE OF A NEGOTIATOR By Pondicherry University MBA Students.pptxLokeshwariOrchid1
 
What is paper chromatography, principal, procedure,types, diagram, advantages...
What is paper chromatography, principal, procedure,types, diagram, advantages...What is paper chromatography, principal, procedure,types, diagram, advantages...
What is paper chromatography, principal, procedure,types, diagram, advantages...srcw2322l101
 
Shots fired Budget Presentation.pdf12312
Shots fired Budget Presentation.pdf12312Shots fired Budget Presentation.pdf12312
Shots fired Budget Presentation.pdf12312LR1709MUSIC
 
wagamamaLab presentation @MIT 20240509 IRODORI
wagamamaLab presentation @MIT 20240509 IRODORIwagamamaLab presentation @MIT 20240509 IRODORI
wagamamaLab presentation @MIT 20240509 IRODORIIRODORI inc.
 

Recently uploaded (20)

Pitch Deck Teardown: Goodcarbon's $5.5m Seed deck
Pitch Deck Teardown: Goodcarbon's $5.5m Seed deckPitch Deck Teardown: Goodcarbon's $5.5m Seed deck
Pitch Deck Teardown: Goodcarbon's $5.5m Seed deck
 
The Art of Decision-Making: Navigating Complexity and Uncertainty
The Art of Decision-Making: Navigating Complexity and UncertaintyThe Art of Decision-Making: Navigating Complexity and Uncertainty
The Art of Decision-Making: Navigating Complexity and Uncertainty
 
Presentation4 (2) survey responses clearly labelled
Presentation4 (2) survey responses clearly labelledPresentation4 (2) survey responses clearly labelled
Presentation4 (2) survey responses clearly labelled
 
Beyond Numbers A Holistic Approach to Forensic Accounting
Beyond Numbers A Holistic Approach to Forensic AccountingBeyond Numbers A Holistic Approach to Forensic Accounting
Beyond Numbers A Holistic Approach to Forensic Accounting
 
Unlocking Growth The Power of Outsourcing for CPA Firms
Unlocking Growth The Power of Outsourcing for CPA FirmsUnlocking Growth The Power of Outsourcing for CPA Firms
Unlocking Growth The Power of Outsourcing for CPA Firms
 
Challenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
Challenges and Opportunities: A Qualitative Study on Tax Compliance in PakistanChallenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
Challenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
 
如何办理(SUT毕业证书)斯威本科技大学毕业证成绩单本科硕士学位证留信学历认证
如何办理(SUT毕业证书)斯威本科技大学毕业证成绩单本科硕士学位证留信学历认证如何办理(SUT毕业证书)斯威本科技大学毕业证成绩单本科硕士学位证留信学历认证
如何办理(SUT毕业证书)斯威本科技大学毕业证成绩单本科硕士学位证留信学历认证
 
Powerpoint showing results from tik tok metrics
Powerpoint showing results from tik tok metricsPowerpoint showing results from tik tok metrics
Powerpoint showing results from tik tok metrics
 
obat aborsi bandung wa 081336238223 jual obat aborsi cytotec asli di bandung9...
obat aborsi bandung wa 081336238223 jual obat aborsi cytotec asli di bandung9...obat aborsi bandung wa 081336238223 jual obat aborsi cytotec asli di bandung9...
obat aborsi bandung wa 081336238223 jual obat aborsi cytotec asli di bandung9...
 
The Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdf
The Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdfThe Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdf
The Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdf
 
Elevate Your Online Presence with SEO Services
Elevate Your Online Presence with SEO ServicesElevate Your Online Presence with SEO Services
Elevate Your Online Presence with SEO Services
 
Obat Aborsi Malang 0851\7696\3835 Jual Obat Cytotec Di Malang
Obat Aborsi Malang 0851\7696\3835 Jual Obat Cytotec Di MalangObat Aborsi Malang 0851\7696\3835 Jual Obat Cytotec Di Malang
Obat Aborsi Malang 0851\7696\3835 Jual Obat Cytotec Di Malang
 
A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...
A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...
A BUSINESS PROPOSAL FOR SLAUGHTER HOUSE WASTE MANAGEMENT IN MYSORE MUNICIPAL ...
 
Navigating Tax Season with Confidence Streamlines CPA Firms
Navigating Tax Season with Confidence Streamlines CPA FirmsNavigating Tax Season with Confidence Streamlines CPA Firms
Navigating Tax Season with Confidence Streamlines CPA Firms
 
Contact +971581248768 for 100% original and safe abortion pills available for...
Contact +971581248768 for 100% original and safe abortion pills available for...Contact +971581248768 for 100% original and safe abortion pills available for...
Contact +971581248768 for 100% original and safe abortion pills available for...
 
Most Visionary Leaders in Cloud Revolution, Shaping Tech’s Next Era - 2024 (2...
Most Visionary Leaders in Cloud Revolution, Shaping Tech’s Next Era - 2024 (2...Most Visionary Leaders in Cloud Revolution, Shaping Tech’s Next Era - 2024 (2...
Most Visionary Leaders in Cloud Revolution, Shaping Tech’s Next Era - 2024 (2...
 
A DAY IN LIFE OF A NEGOTIATOR By Pondicherry University MBA Students.pptx
A DAY IN LIFE OF A NEGOTIATOR By Pondicherry University MBA Students.pptxA DAY IN LIFE OF A NEGOTIATOR By Pondicherry University MBA Students.pptx
A DAY IN LIFE OF A NEGOTIATOR By Pondicherry University MBA Students.pptx
 
What is paper chromatography, principal, procedure,types, diagram, advantages...
What is paper chromatography, principal, procedure,types, diagram, advantages...What is paper chromatography, principal, procedure,types, diagram, advantages...
What is paper chromatography, principal, procedure,types, diagram, advantages...
 
Shots fired Budget Presentation.pdf12312
Shots fired Budget Presentation.pdf12312Shots fired Budget Presentation.pdf12312
Shots fired Budget Presentation.pdf12312
 
wagamamaLab presentation @MIT 20240509 IRODORI
wagamamaLab presentation @MIT 20240509 IRODORIwagamamaLab presentation @MIT 20240509 IRODORI
wagamamaLab presentation @MIT 20240509 IRODORI
 

Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf

  • 1. Biopharma PEG https://www.biochempeg.com Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials The development of oligonucleotide-based gene therapies has been in full swing over the past few years due to their unique advantage of regulating gene expression. Oligonucleotides are short DNA or RNA oligomers between 20 and 60 units in length, which can be synthesized or found naturally as single-stranded (ss) or double-stranded (ds) oligomers. The introduction of oligonucleotide drugs has broadened the means and boundaries of disease treatment and brought new hope for the treatment of many diseases. However, unmodified oligonucleotides are difficult to cross through the cellular membrane and blood-brain barrier due to their high molecular weight, high hydrophilicity and negative charge, as well as their low in vivo stability and rapid host clearance outside cells. Currently, the main approved oligonucleotide drug delivery systems are the LNP delivery system and the GalNAc delivery system, but neither is capable of drug-targeted delivery outside the liver. An emerging strategy to deliver oligonucleotides to tissues outside of the liver is by linking them to monoclonal antibodies (mAbs), to form antibody– oligonucleotide conjugates (AOCs). AOC Drugs Market Landscape Currently, a number of companies are working in the AOC space, mainly including Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, and Denali Therapeutics. Avidity Biosciences (AOC 1001, AOC 1020) Avidity Biosciences, founded in 2013, is a biopharmaceutical company that is pioneering AOC therapies for the treatment of inherited muscle diseases. At its inception , Avidity envisioned tissue-specific delivery of small interfering RNA (siRNA)-nanoparticles via antibodies, but that didn't go well, as antibodies are difficult to achieve effective delivery of
  • 2. Biopharma PEG https://www.biochempeg.com siRNA-nanoparticles. To ensure effective loading, the researchers tried to conjugate antibodies directly to siRNA, which led to the design of the AOC drug. Avidity's AOC programs mainly offer treatment options for patients with myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne Muscular Dystrophy (DMD), etc. Figure. Avidity Biosciences Pipeline, source: Avidity Biosciences official website AOC1001 AOC 1001, Avidity's lead product candidate developed for the treatment of dystrophic myotonic dystrophy type 1 (DM1), consists of a proprietary monoclonal antibody that binds to the transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DMPK mRNA, which is designed to address the root cause of DM1 by reducing levels of DMPK RNA. Avidity is currently conducting the Phase I/II MARINA and MARINA-OLE studies of AOC 1001 for the treatment of DM1, and AOC 1001 is the first AOC drug to enter the clinic.
  • 3. Biopharma PEG https://www.biochempeg.com Figure. AOC-1001 for DM1, source: Avidity Biosciences official website In preclinical studies, AOC 1001 successfully delivered siRNA to muscle cells, resulting in a long-lasting, dose-dependent reduction of DMPK RNA in a variety of muscles, including skeletal, cardiac, and smooth muscle. Avidity announced positive topline data for AOC 1001 from the Phase 1/2 MARINA trial at the 75th Annual Meeting of the American Academy of Neurology (AAN) in April 2023, which demonstrated functional improvement in multiple clinical outcome metrics, disease modification, and favorable safety and tolerability profiles for adult DM1 patients. FDA and EMA have granted Orphan Designation for AOC 1001 and the FDA has granted AOC 1001 Fast Track Designation. AOC1020 AOC1020, an AOC drug consisting of a TfR1 antibody coupled to a siRNA targeting DUX4 mRNA, was developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD). FSHD is one of the most common clinically inherited muscle disorders caused by aberrant expression of the DUX4 gene in skeletal muscle, leading to skeletal muscle atrophy and impaired muscle function through a series of downstream events. There are currently no approved therapeutic options for this disease, and medical care is primarily focused on physical therapy, exercise, pain management, and orthopedic
  • 4. Biopharma PEG https://www.biochempeg.com interventions, with other therapies in development that do not directly target DUX4 as a disease driver. Figure. AOC1020 for FSHD, source: Avidity Biosciences official website Preclinical data show that AOC 1020 inhibits DUX4 mRNA expression, decreasing DUX4 protein levels and reducing downstream gene expression. AOC 1020 is currently in Phase 1/2 development as part of the FORTITUDE™ trial in adults with FSHD. The FDA and the EMA have granted Orphan designation for AOC 1020 and the FDA has granted AOC 1020 Fast Track designation. Dyne Therapeutics(DYNE-101, DYNE-251) Dyne Therapeutics is a biopharmaceutical company developing targeted therapies for serious muscle diseases. The company focuses on three major rare muscle diseases, including DM1, DMD and FSHD. Dyne is developing novel oligonucleotide therapies with its proprietary FORCE™ platform, which targets the TFR-1 receptor, a highly expressed receptor on the surface of muscle cells, and engineers therapeutic molecules by ligating antibodies to oligonucleotides for the treatment of severe muscle diseases.
  • 5. Biopharma PEG https://www.biochempeg.com Figure. Dyne Therapeutics pipeline, source: Dyne Therapeutics official website DYNE-101 DYNE-101 is an investigational AOC being evaluated in the Phase I/II global ACHIEVE trial, for treatment of DM1. It consists of an antigen-binding fragment antibody (Fab) conjugated to an antisense oligonucleotide (ASO) designed to enable targeted muscle tissue delivery that reduces toxic DMPK RNA in the nucleus, releases splicing proteins, allows normal mRNA processing and translation of normal proteins, and potentially stops or reverses disease. In May 2023, the EMA has granted orphan drug designation for DYNE-101. DYNE-251 DYNE-251 is an AOC developed for patients with DMD amenable to skipping exon 51, consisting of a phosphorodiamidate morpholino oligomer (PMO) conjugated to a Fab fragment. DYNE-251 can target binding to TfR1, which is highly expressed in the target muscle tissues. It is designed to enable targeted muscle tissue delivery and promote exon skipping in the nucleus, allowing muscle cells to create a truncated, functional dystrophin protein, with the goal of stopping or reversing disease progression. DYNE-251 is currently in Phase I/II DELIVER global clinical trials. Previously, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for DYNE-251. Tallac Therapeutics (TAC-001)
  • 6. Biopharma PEG https://www.biochempeg.com Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac's immunotherapy candidate pipeline stems from the company's novel Toll-like receptor agonist antibody conjugate (TRAAC) platform, to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Figure. Tallac Therapeutics pipelines, source: Tallac Therapeutics official website TAC-001 TAC-001, an important drug candidate for Tallac, is an AOC consisting of a potent toll-like receptor 9 agonist (T-CpG) conjugated to an antibody against CD22, which delivers T-CpG to B cells by binding to CD22, which in turn leads to internalization of TAC-001 as well as TLR9 signaling, B cell activation, and a series of immune responses. The innate and adaptive immune responses triggered by TAC-001 show potent, curative, and durable single-agent antitumor activity in checkpoint inhibitor-resistant and refractory tumor models. TAC-001 is currently in Phase I/II clinical stage for the potential treatment of solid tumors. Denali Therapeutics (DNL310) Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases, has developed a proprietary transport vehicle (TV) technology platform that enables therapeutic biomolecules, including enzymes, antibodies, proteins, and oligonucleotides, to cross the blood-brain barrier more efficiently. In addition, Denali
  • 7. Biopharma PEG https://www.biochempeg.com regards TfR1 as a gateway to the brain. Cells lining the blood-brain barrier express TfR1, making TfR1 an ideal pathway for oligonucleotides, proteins and antibody drugs to enter the central nervous system. DNL310 DNL310 is a fusion protein drug consisting of an IDS protein bound to Denali's Enzymatic Transport Vehicle (ETV). Denali's ETV platform contains engineered Fc fragments that bind to natural transport receptors, such as transferrin receptor, which are expressed at the BBB and deliver TV and its therapeutic cargo to the brain through receptor-mediated transcytosis. DNL310 delivers IDS to lysosomes, where it is needed to break down GAGs. DNL310 is engineered for broad delivery of IDS into cells and tissues throughout the body, including the brain. Figure. DNL310 mechanism of action, source: Denali Therapeutics official website In March 2021, the U.S. FDA granted Fast Track designation to DNL310 for the treatment of MPS II. In May 2022, the EMA granted DNL310 Priority Medicines designation. In June 2023, Denali announced Phase I/II clinical results for DNL310 for the treatment of MPS II. The data showed a significant reduction in serum Neurofilament Light (NfL) levels of up to 64% in MPS II patients compared to baseline. A clinical Phase II/III trial of DNL310 is currently underway worldwide. Conclusion
  • 8. Biopharma PEG https://www.biochempeg.com Currently, there are only a few AOC drugs under development, and the progress is a little behind compared with other drug conjugates, the effectiveness, and safety still need to be further certified, leaving a long way to go before they can be routinely used in the clinic. However, nucleic acid drugs are regarded as the third wave of biopharmaceuticals and large molecule biopharmaceuticals, and oligonucleotide therapy itself has been approved in the past few years for the treatment of rare diseases, which fully proves the efficacy and safety of this therapy. In this case, it can be expected that AOC, as a new type of drug conjugate, will make a breakthrough in the field of rare disease therapy. References: 1. Antibody–oligonucleotide conjugates enter the clinic. Nature Reviews Drug Discovery. 2. https://www.sec.gov/Archives/edgar/data/1599901/000119312521232444/d203435dex 991.htm 3. https://www.aviditybiosciences.com/wp-content/uploads/2023/04/P.3.007-FORTITUDE -TIP_AAN-2023_ELECTRONIC-Poster_v5.0_Final.pdf 4. https://www.dyne-tx.com/ 5. https://www.biospace.com/article/releases/dyne-therapeutics-receives-european-medi cines-agency-ema-orphan-drug-designation-for-dyne-101/?s=63. 6. https://www.tallactherapeutics.com/news/tallac-therapeutics-announces-first-patient-do sed-with-tac-001-a-first-in-class-toll-like-receptor-9-agonist-antibody-conjugate-in-a-phas e-1-2-study-for-patients-with-advanced-solid-tumors/ 7. Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome). Retrieved June 20, 2023 from https://www.denalitherapeutics.com/investors/press-release?id=9391&type=api. Related Articles: 9 Types of Drug Conjugates Overview Small Molecule-Drug Conjugates (SMDCs): Novel Targeted Therapy Aptamer-Drug Conjugate (ApDC): Current Research Progress Peptide-Drug Conjugates (PDCs): Development Status & Research Progress